This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leyland-Jones, B. Articles by Hiorns, L. R. Search for Related Content PubMed PubMed Citation Articles by Leyland-Jones, B. Articles by Hiorns, L. R.

(American Journal of Pathology. 1999;155:77-84.)
© 1999 American Society for Investigative Pathology

Short Communication

Genomic Imbalances Associated with Acquired Resistance to Platinum Analogues

Brian Leyland-Jones^*, Lloyd R. Kelland, Kenneth R. Harrap and Lynne R. Hiorns

From the Department of Oncology,^*
McGill University, Montreal, Quebec, Canada; the CRC Centre for Cancer Therapeutics,
and Academic Department of Haematology & Cytogenetics,
Institute of Cancer Research, Sutton, Surrey, United Kingdom

During the past several years, a panel of human tumor cell lines (predominantly ovarian) with acquired resistance to cisplatin, the orally bioavailable analogue JM216, and the structurally hindered analogue AMD473, has been established and characterized for underlying mechanisms of resistance. We have examined these resistant cell lines for gains and losses of DNA associated with the acquisition of resistance using the molecular cytogenetic technique of comparative genomic hybridization. Our comparison of three analogues has shown the most frequently observed changes to include amplification of 4q (5/7) and 6q (5/7), followed by amplification of 5q (3/7). We have defined four minimal common overrepresented regions, two each on 4q and 6q, which are potential loci of genes associated with platinum analogue resistance. Additional consistent abnormalities appear to be associated with cell lines sharing specific resistance mechanisms. For example, amplification of 12q was observed in the CH1 lines made respectively resistant to JM216 and AMD473 in which increased DNA repair appears to be a major mechanism of resistance for both agents. Hence, these comparative genomic hybridization studies have identified distinct chromosomal aberrations which may correlate with defined mechanisms of resistance and contain hitherto unrecognized genes that may provide targets for future therapeutic intervention.

This article has been cited by other articles:

				K. Yasui, S. Mihara, C. Zhao, H. Okamoto, F. Saito-Ohara, A. Tomida, T. Funato, A. Yokomizo, S. Naito, I. Imoto, et al. Alteration in Copy Numbers of Genes as a Mechanism for Acquired Drug Resistance Cancer Res., February 15, 2004; 64(4): 1403 - 1410. [Abstract] [Full Text] [PDF]

				P. Duesberg, R. Stindl, and R. Hehlmann Origin of multidrug resistance in cells with and without multidrug resistance genes: Chromosome reassortments catalyzed by aneuploidy PNAS, September 5, 2001; (2001) 201398998. [Abstract] [Full Text] [PDF]

				P. Duesberg, R. Stindl, and R. Hehlmann Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy PNAS, December 19, 2000; 97(26): 14295 - 14300. [Abstract] [Full Text] [PDF]

				P. Duesberg, R. Stindl, and R. Hehlmann Origin of multidrug resistance in cells with and without multidrug resistance genes: Chromosome reassortments catalyzed by aneuploidy PNAS, September 25, 2001; 98(20): 11283 - 11288. [Abstract] [Full Text] [PDF]